Document is current
Any future updates will be listed below
-
Authors
Lee, Choong-kun
Lee, Jii Bum
Park, Se Jung
Che, Jingmin
Kwon, Woo Sun
Kim, Hyo Song
Jung, Minkyu
Lee, Seulkee
Park, Sook Ryun
Koo, Dong-Hoe
Lee, Hyun Woo
Bae, Woo Kyun
Jeung, Hei-Cheul
Hwang, In Gyu
Kim, Hyunki
Nam, Chung Mo
Chung, Hyun Cheol
Rha, Sun Young https://orcid.org/0000-0002-2512-4531
-
Funding
Funding for this research was provided by:
National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1520190)
Basic Science Research Program, through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning (2017R1A2B200577)
National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF-2020R1C1C1004461)
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 29 September 2023
First Online: 31 October 2023
Declarations
:
: H.C.C. reported grants/research support from Eli Lilly, GlaxoSmithKline, MSD, Merck-Serono, Bristol-Myers Squibb, Taiho, Amgen, Beigene, Incyte, Zymework, honoraria from Merck-Serono, Eli Lilly, and consultation for Taiho, Celltrion, MSD, Eli Lilly, Bristol-Myers Squibb, Merck-Serono, Gloria, Beigene, Amgen, Zymework, outside the submitted work. S.Y.R. reported grant/research support from MSD, Celltrion, Boehringer-Ingelheim, Eli Lilly, Taiho, Bristol-Myers Squibb, ASLAN, Incyte, consultation for Daiichi Sankyo, MSD, Eli Lilly, Bristol-Myers Squibb, Eisai, and speaker’s bureau for Eli Lilly, Bristol-Myers Squibb, MSD, outside the submitted work. The other authors declare no potential conflicts of interest.
: This trial was conducted under the Declaration of Helsinki and the Guidelines for Good Clinical Practice. Its protocol was approved by the institutional review boards of each institution. All patients provided written informed consent before enrollment.
